This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic +10 more
wiley +1 more source
Non-Operative Management of Esophageal Cancer with Complete Clinical Response After Neoadjuvant Therapy: Current Status and Future Directions. [PDF]
Bertona S, Castillo J, Schlottmann F.
europepmc +1 more source
Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study. [PDF]
Rudlowski C +3 more
europepmc +1 more source
Gut microbiota alterations in patients with non‐small‐cell lung cancer undergoing chemoradiotherapy
We investigated the impact of concurrent chemoradiotherapy (CRT) on the gut microbiota in patients with locally advanced non‐small‐cell lung cancer. Overall gut microbiota composition remained largely stable throughout CRT while antibiotic exposure may influence microbial diversity.
Hanne Marte Nymoen +19 more
wiley +1 more source
Pelvic MRI Following Total Neoadjuvant Therapy for Rectal Cancer Poorly Predicts a Complete Clinical Response. [PDF]
Suss NR +6 more
europepmc +1 more source
Extracellular vesicle (EV) lipidomic profiling of plasma and ascites from patients with high‐grade serous ovarian cancer and of ovarian cancer cell lines reveals enrichment of triglycerides (TGs), diacylglycerols (DGs), phosphatidylcholine (PCs), sphingomyelins (SMs), reflecting tumor metabolic reprogramming.
Shikha Rani +9 more
wiley +1 more source
Use of artificial intelligence in analysis of endoscopic images to detect residual disease or regrowth in rectal patients with complete clinical response to neoadjuvant chemoradiotherapy. [PDF]
Javed MA +8 more
europepmc +1 more source
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira +7 more
wiley +1 more source
Connecticut State Emergency Response Commission [web site] [Harvested on 2012: Aug. 10]
Updated irregularly; Began in 2002?; Title from home page (publisher's Web site, viewed June 1, 2011).; At head of title: State of Connecticut.; Official website of the Connecticut State Emergency Response Commission.
core

